

Eline van Overbeeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216322/publications.pdf>

Version: 2024-02-01

22
papers

607
citations

687220

13
h-index

677027

22
g-index

23
all docs

23
docs citations

23
times ranked

636
citing authors

#	ARTICLE	IF	CITATIONS
1	Examining patient and professional perspectives in the UK for gene therapy in haemophilia. Haemophilia, 2022, 28, 588-609.	1.0	5
2	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. Haemophilia, 2021, 27, 129-136.	1.0	27
3	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today, 2021, 26, 399-415.	3.2	20
4	Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives. Patient, 2021, 14, 119-128.	1.1	23
5	Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study. Patient, 2021, 14, 601-612.	1.1	8
6	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. Frontiers in Medicine, 2021, 8, 595797.	1.2	8
7	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. Haemophilia, 2021, 27, 957-966.	1.0	14
8	Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. Frontiers in Medicine, 2020, 7, 407.	1.2	6
9	An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?. Health Policy, 2020, 124, 1325-1332.	1.4	28
10	Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. Frontiers in Medicine, 2020, 7, 157.	1.2	20
11	Improving Patient Involvement in the Lifecycle of Medicines: Insights From the EUPATI BE Survey. Frontiers in Medicine, 2020, 7, 36.	1.2	4
12	Patient Centricity in Patient Preference Studies: The Patient Perspective. Frontiers in Medicine, 2020, 7, 93.	1.2	14
13	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. Wellcome Open Research, 2020, 5, 253.	0.9	4
14	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. Frontiers in Pharmacology, 2019, 10, 1009.	1.6	16
15	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. BMC Medical Informatics and Decision Making, 2019, 19, 189.	1.5	36
16	Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. Patient, 2019, 12, 513-526.	1.1	24
17	Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet Journal of Rare Diseases, 2019, 14, 99.	1.2	65
18	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today, 2019, 24, 1324-1331.	3.2	90

#	ARTICLE	IF	CITATIONS
19	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1395.	1.6	48
20	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 57-68.	3.2	69
21	Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice. <i>Frontiers in Medicine</i> , 2018, 5, 285.	1.2	13
22	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. <i>BioDrugs</i> , 2017, 31, 447-459.	2.2	65